Ronald Fields, MD
Critical Care Medicine · Baton Rouge, LANPI 1962498196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 527 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,858, 3.7 times the $770 reported in 2019.
Across 527 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Boehringer Ingelheim$1K
- Sanofi$1K
- AstraZeneca$968
- Grifols USA, LLC$510
- United Therapeutics Corporation$491
- plus $5K from 41 others
What the payments were for
- Food & beverage$10,64298%
- Education$2242%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$10,866 in reported general payments places this provider in the 85th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,166 | $939,991 |
| OfevNintedanib Esylate | 20 | $257,093 |
| UptraviSelexipag | 12 | $172,499 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 97 | $85,237 |
| Spiriva RespimatTiotropium Bromide | 110 | $77,986 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $67,379 |
| Dupixent PenDupilumab | 16 | $60,122 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $58,575 |
| Spiriva HandihalerTiotropium Bromide | 65 | $49,068 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 81 | $39,184 |
| SymbicortBudesonide/Formoterol Fumarate | 107 | $30,640 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 930 | $29,690 |
| EliquisApixaban | 43 | $25,407 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $15,042 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $11,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,853 | $1,072,1831,484 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,195 | $393,654216 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $449 | $172,49912 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $968 | $119,420215 claims |
| PfizerEliquis | $120 | $25,40743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 72 critical care medicine providers in Louisiana.
Other critical care medicine in Baton Rouge
- Abdulla Majid-MoosaBaton Rouge$202K
- Ahmad SharayahBaton Rouge$12K
- Merissa BraudBaton Rouge$8K
- James VermaelenBaton Rouge$8K
- Mostafa AboubakrBaton Rouge$6K
- James FordBaton Rouge$6K
- Vincent ValentineBaton Rouge$6K
- Daniel ReesBaton Rouge$4K
- Owen StellBaton Rouge$3K
- Dena LandryBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.